Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity.
Aged
Cardiotoxicity
/ complications
Contrast Media
Edema
/ diagnostic imaging
Female
Fibrosis
/ diagnostic imaging
Gadolinium
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Inflammation
/ diagnostic imaging
Magnetic Resonance Imaging
Magnetic Resonance Imaging, Cine
Male
Middle Aged
Myocarditis
/ complications
Ventricular Dysfunction, Left
/ complications
Ventricular Function, Left
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
11
2020
accepted:
25
01
2021
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer; however, cardiotoxicity can occur, including myocarditis. Cardiac magnetic resonance (CMR) imaging is useful for evaluation of myocarditis, although it has not been well studied in ICI cardiotoxicity. We identified patients referred for CMR evaluation of ICI cardiotoxicity from September 2015 through September 2019. We assessed structural and functional parameters, feature tracking (FT) left ventricular and atrial strain, T2- weighted ratios and quantitative late gadolinium enhancement (LGE). We also applied the Updated Lake Louise Criteria for diagnosis of myocarditis. Of the 20 patients referred, the median left ventricular ejection fraction (LVEF) was 52.5% ± 19.1 and 50% had a normal LVEF (≥53%). FT strain analysis revealed an average abnormal global longitudinal strain (GLS) of -9.8%± 4.2%. In patients with a normal LVEF, the average GLS remained depressed at -12.3%± 2.4%. In all patients, GLS demonstrated a significant negative correlation with LVEF (rs = -0.64, p 0.002). Sixteen patients (80%) had presence of LGE (14 non-ischemic pattern and 2 ischemic). Percent LGE did not correlate with any CMR parameters and notably did not correlate with LVEF (rs = -0.29, p = 0.22) or GLS (rs = 0.10, p = 0.67), highlighting the value of tissue characterization beyond functional assessment. Nine patients (45%) met full Updated Lake Louise Criteria and 85% met at least one criterion, suggestive of myocarditis in the correct clinical context. Thirteen patients (65%) were treated for ICI-associated myocarditis and, of these, 54% (n = 7) had recovery of LVEF to normal. There was no correlation between LVEF (p = 0.47), GLS (0.89), or % LGE (0.15) and recovery of LVEF with treatment. In patients with suspected ICI cardiotoxicity, CMR is an important diagnostic tool, even in the absence of overt left ventricular dysfunction, as abnormalities in left ventricular strain, T2 signal and LGE can identifying disease.
Sections du résumé
BACKGROUND
Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer; however, cardiotoxicity can occur, including myocarditis. Cardiac magnetic resonance (CMR) imaging is useful for evaluation of myocarditis, although it has not been well studied in ICI cardiotoxicity.
METHODS
We identified patients referred for CMR evaluation of ICI cardiotoxicity from September 2015 through September 2019. We assessed structural and functional parameters, feature tracking (FT) left ventricular and atrial strain, T2- weighted ratios and quantitative late gadolinium enhancement (LGE). We also applied the Updated Lake Louise Criteria for diagnosis of myocarditis.
RESULTS
Of the 20 patients referred, the median left ventricular ejection fraction (LVEF) was 52.5% ± 19.1 and 50% had a normal LVEF (≥53%). FT strain analysis revealed an average abnormal global longitudinal strain (GLS) of -9.8%± 4.2%. In patients with a normal LVEF, the average GLS remained depressed at -12.3%± 2.4%. In all patients, GLS demonstrated a significant negative correlation with LVEF (rs = -0.64, p 0.002). Sixteen patients (80%) had presence of LGE (14 non-ischemic pattern and 2 ischemic). Percent LGE did not correlate with any CMR parameters and notably did not correlate with LVEF (rs = -0.29, p = 0.22) or GLS (rs = 0.10, p = 0.67), highlighting the value of tissue characterization beyond functional assessment. Nine patients (45%) met full Updated Lake Louise Criteria and 85% met at least one criterion, suggestive of myocarditis in the correct clinical context. Thirteen patients (65%) were treated for ICI-associated myocarditis and, of these, 54% (n = 7) had recovery of LVEF to normal. There was no correlation between LVEF (p = 0.47), GLS (0.89), or % LGE (0.15) and recovery of LVEF with treatment.
CONCLUSION
In patients with suspected ICI cardiotoxicity, CMR is an important diagnostic tool, even in the absence of overt left ventricular dysfunction, as abnormalities in left ventricular strain, T2 signal and LGE can identifying disease.
Identifiants
pubmed: 33606757
doi: 10.1371/journal.pone.0246764
pii: PONE-D-20-35516
pmc: PMC7895343
doi:
Substances chimiques
Contrast Media
0
Immune Checkpoint Inhibitors
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246764Subventions
Organisme : NCI NIH HHS
ID : R01 CA227473
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL144706
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JACC Cardiovasc Imaging. 2015 Jan;8(1):37-46
pubmed: 25499131
J Am Coll Cardiol. 2009 Apr 28;53(17):1475-87
pubmed: 19389557
J Cardiovasc Magn Reson. 2018 Apr 19;20(1):26
pubmed: 29669563
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):196-205
pubmed: 28528164
Eur Heart J Cardiovasc Imaging. 2016 Feb;17(2):154-61
pubmed: 26476398
J Am Coll Cardiol. 2020 Feb 11;75(5):467-478
pubmed: 32029128
Am J Cardiol. 2015 Aug 1;116(3):436-41
pubmed: 26026863
Br J Pharmacol. 2017 Nov;174(22):3940-3955
pubmed: 28369782
Cancer Immunol Res. 2017 Apr;5(4):312-318
pubmed: 28246107
J Am Soc Echocardiogr. 2014 Sep;27(9):911-39
pubmed: 25172399
Eur J Radiol. 2018 Jul;104:120-128
pubmed: 29857857
Case Rep Oncol. 2018 Oct 22;11(3):648-653
pubmed: 30483092
JAMA Oncol. 2019 Jul 1;5(7):1008-1019
pubmed: 31021376
Mayo Clin Proc. 1989 Oct;64(10):1235-45
pubmed: 2593714
J Cardiovasc Magn Reson. 2009 Dec 30;11:56
pubmed: 20042111
Am J Physiol Heart Circ Physiol. 2016 Mar 1;310(5):H542-9
pubmed: 26747498
PLoS One. 2018 Nov 28;13(11):e0208100
pubmed: 30485353
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Eur Heart J Case Rep. 2019 Jan 07;3(1):yty149
pubmed: 31020225
Circ Cardiovasc Imaging. 2017 Feb;10(2):
pubmed: 28213448
J Oncol Pract. 2018 Apr;14(4):247-249
pubmed: 29517954
J Immunother Cancer. 2016 Aug 16;4:50
pubmed: 27532025
Front Pharmacol. 2019 Nov 29;10:1350
pubmed: 31849640
J Cardiovasc Magn Reson. 2017 Aug 2;19(1):59
pubmed: 28768517
J Cancer Res Clin Oncol. 2019 Jun;145(6):1527-1557
pubmed: 31028541
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
Int J Cardiovasc Imaging. 2017 Oct;33(10):1561-1569
pubmed: 28421305
J Cardiovasc Magn Reson. 2016 Aug 26;18(1):51
pubmed: 27561421
Eur Heart J Cardiovasc Imaging. 2019 Jun 1;20(6):605-619
pubmed: 30903139
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
Comput Biol Med. 2018 Jan 1;92:197-203
pubmed: 29227821
Mayo Clin Proc. 2011 Nov;86(11):1095-102
pubmed: 22033254
Clin Res Cardiol. 2020 Jul;109(7):869-880
pubmed: 31828505
Int J Cardiol. 2017 Mar 15;231:216-221
pubmed: 27913009
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855
pubmed: 30482962
Eur Heart J. 2020 May 7;41(18):1744-1746
pubmed: 32176277
Cardiovasc Res. 2019 Apr 15;115(5):854-868
pubmed: 30715219
J Am Coll Cardiol. 2012 May 1;59(18):1604-15
pubmed: 22365425
Eur Heart J. 2020 May 7;41(18):1733-1743
pubmed: 32112560
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
Ann Oncol. 2017 Nov 1;28(11):2893-2895
pubmed: 28651328
Circulation. 2020 Dec 15;142(24):2299-2311
pubmed: 33003973